Foresee Pharmaceuticals Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	519.61	418.69	195.04	301.51	226.03	230.44
Revenue Growth (YoY)	49.93%	114.67%	-35.31%	33.39%	-1.91%	206.44%
Cost of Revenue	138.75	178.89	81.07	25.54	50.95	57.01
Gross Profit	380.86	239.8	113.97	275.97	175.08	173.43
Selling, General & Admin	166.21	147.32	160.16	124.23	99.07	120.58
Research & Development	1,430	1,172	961.44	621.18	614.64	537.65
Operating Expenses	1,597	1,320	1,122	745.41	713.71	658.23
Operating Income	-1,216	-1,080	-1,008	-469.44	-538.63	-484.79
Interest Expense	-5.7	-6.71	-2.85	-0.4	-0.68	-1
Interest & Investment Income	19.14	28.28	23.53	8.34	3.53	1.04
Currency Exchange Gain (Loss)	-16.39	21.51	-2.32	23.35	-3.05	1.37
Other Non Operating Income (Expenses)	11.59	3.26	0.83	1.2	10.17	0.1
EBT Excluding Unusual Items	-1,207	-1,033	-988.45	-436.96	-528.66	-483.28
Gain (Loss) on Sale of Investments	-	-	-	0.29	0.8	0.52
Gain (Loss) on Sale of Assets	-	-0.03	-0.2	-0.31	-0.13	-0.06
Asset Writedown	-	-	-	-1.16	-	-
Other Unusual Items	-	0.28	0.01	-	-	-
Pretax Income	-1,207	-1,033	-988.64	-438.13	-527.99	-482.81
Income Tax Expense	18.55	47.87	47.67	34.51	41.28	27.9
Net Income	-1,226	-1,081	-1,036	-472.64	-569.27	-510.71
Net Income to Common	-1,226	-1,081	-1,036	-472.64	-569.27	-510.71
Shares Outstanding (Basic)	151	137	127	118	117	101
Shares Outstanding (Diluted)	151	137	127	118	117	101
Shares Change (YoY)	10.78%	7.89%	7.82%	0.57%	15.74%	5.71%
EPS (Basic)	-8.13	-7.87	-8.14	-4.00	-4.85	-5.04
EPS (Diluted)	-8.13	-7.87	-8.14	-4.00	-4.85	-5.04
Free Cash Flow	-1,363	-1,323	-933.84	-291.29	-220.19	-687.58
Free Cash Flow Per Share	-9.04	-9.64	-7.34	-2.47	-1.88	-6.78
Gross Margin	73.30%	57.27%	58.44%	91.53%	77.46%	75.26%
Operating Margin	-233.98%	-257.90%	-516.63%	-155.70%	-238.30%	-210.38%
Profit Margin	-235.89%	-258.20%	-531.33%	-156.76%	-251.86%	-221.63%
Free Cash Flow Margin	-262.35%	-316.07%	-478.80%	-96.61%	-97.42%	-298.38%
EBITDA	-1,160	-1,016	-950.68	-429.72	-498.38	-446.65
EBITDA Margin	-223.16%	-242.56%	-	-142.52%	-220.50%	-193.82%
D&A For EBITDA	56.21	64.2	56.95	39.72	40.24	38.14
EBIT	-1,216	-1,080	-1,008	-469.44	-538.63	-484.79
EBIT Margin	-233.98%	-257.90%	-	-155.70%	-238.30%	-210.38%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.